AAPL323.12+6.27 (+1.98%) ▲|ABBV259.94+3.52 (+1.37%) ▲|ABT109.72-0.65 (-0.58%) ▼|ACN188.13-1.63 (-0.86%) ▼|ADBE288.66-4.13 (-1.41%) ▼|AMAT444.40-13.99 (-3.05%) ▼|AMD457.06-13.66 (-2.90%) ▼|AMGN433.06+3.18 (+0.74%) ▲|AMT175.51-0.19 (-0.11%) ▼|AMZN254.66-5.12 (-1.97%) ▼|AVGO367.78-2.56 (-0.69%) ▼|AXP326.86-3.32 (-1.00%) ▼|BA206.77-1.01 (-0.49%) ▼|BAC62.37+0.43 (+0.69%) ▲|BKNG199.46+0.37 (+0.18%) ▲|BLK1,136.45-19.16 (-1.66%) ▼|BMY67.03+0.22 (+0.32%) ▲|BNY160.60-0.68 (-0.42%) ▼|BRK-B504.70+0.67 (+0.13%) ▲|C133.09+1.47 (+1.11%) ▲|CAT781.69-15.78 (-1.98%) ▼|CL90.56+0.74 (+0.83%) ▲|CMCSA26.55-0.07 (-0.26%) ▼|COF213.56-0.96 (-0.45%) ▼|COP135.00+2.51 (+1.89%) ▲|COST945.38+1.49 (+0.16%) ▲|CRM257.80+0.26 (+0.10%) ▲|CSCO109.17-1.33 (-1.20%) ▼|CVS97.09+3.18 (+3.39%) ▲|CVX208.95+2.81 (+1.36%) ▲|DE672.81+17.90 (+2.73%) ▲|DHR209.33-4.24 (-1.98%) ▼|DIS107.52-0.03 (-0.03%) ▼|DUK120.65+0.74 (+0.61%) ▲|EMR149.65-2.79 (-1.83%) ▼|FDX324.60-2.80 (-0.86%) ▼|GD369.27-2.09 (-0.56%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV884.54-13.99 (-1.56%) ▼|GILD148.38+2.04 (+1.39%) ▲|GM86.22-0.10 (-0.12%) ▼|GOOG332.96-2.45 (-0.73%) ▼|GOOGL336.07-3.29 (-0.97%) ▼|GS1,021.55+0.65 (+0.06%) ▲|HD321.78-6.06 (-1.85%) ▼|HON210.33-3.20 (-1.50%) ▼|IBM231.12-2.75 (-1.18%) ▼|INTC88.80-0.71 (-0.79%) ▼|INTU349.87-9.43 (-2.62%) ▼|ISRG368.92-7.94 (-2.11%) ▼|JNJ268.15+2.30 (+0.86%) ▲|JPM358.40+2.38 (+0.67%) ▲|KO88.53-0.14 (-0.16%) ▼|LIN483.89-5.69 (-1.16%) ▼|LLY1,171.93+15.20 (+1.31%) ▲|LMT551.37-6.41 (-1.15%) ▼|LOW201.78-2.92 (-1.43%) ▼|LRCX291.64-9.85 (-3.27%) ▼|MA587.12-2.19 (-0.37%) ▼|MCD261.14-0.54 (-0.21%) ▼|MDLZ62.38+0.31 (+0.50%) ▲|MDT91.80+1.15 (+1.27%) ▲|META578.60+6.26 (+1.09%) ▲|MMM170.74-1.09 (-0.63%) ▼|MO70.38+1.90 (+2.77%) ▲|MRK149.39+1.63 (+1.10%) ▲|MS214.04+0.72 (+0.34%) ▲|MSFT501.12-6.18 (-1.22%) ▼|MU954.46-4.28 (-0.45%) ▼|NEE82.79+0.45 (+0.55%) ▲|NFLX80.88-0.18 (-0.22%) ▼|NKE38.36-0.30 (-0.76%) ▼|NOW143.09-4.91 (-3.31%) ▼|NVDA218.48-2.02 (-0.92%) ▼|ORCL142.52-6.60 (-4.43%) ▼|PEP140.01-0.33 (-0.24%) ▼|PFE28.64+0.18 (+0.61%) ▲|PG147.83+2.71 (+1.87%) ▲|PLTR183.27-3.11 (-1.67%) ▼|PM190.77+3.47 (+1.85%) ▲|QCOM165.61-4.87 (-2.86%) ▼|RTX206.16-1.58 (-0.76%) ▼|SBUX105.83-0.42 (-0.40%) ▼|SCHW108.78-1.04 (-0.95%) ▼|SO88.11+0.11 (+0.13%) ▲|SPG213.04+0.72 (+0.34%) ▲|T26.07+0.18 (+0.70%) ▲|TMO604.86-12.24 (-1.98%) ▼|TMUS181.95+1.51 (+0.84%) ▲|TSLA359.27-8.68 (-2.36%) ▼|TXN253.38-7.53 (-2.89%) ▼|UBER75.44-0.21 (-0.28%) ▼|UNH395.95+6.54 (+1.68%) ▲|UNP293.91-6.76 (-2.25%) ▼|UPS102.78-1.46 (-1.40%) ▼|USB61.23-0.36 (-0.58%) ▼|V376.86-2.52 (-0.66%) ▼|VZ50.30+0.28 (+0.55%) ▲|WFC86.87+0.48 (+0.55%) ▲|WMT106.07+1.20 (+1.14%) ▲|XOM163.12+2.17 (+1.35%) ▲|AAPL323.12+6.27 (+1.98%) ▲|ABBV259.94+3.52 (+1.37%) ▲|ABT109.72-0.65 (-0.58%) ▼|ACN188.13-1.63 (-0.86%) ▼|ADBE288.66-4.13 (-1.41%) ▼|AMAT444.40-13.99 (-3.05%) ▼|AMD457.06-13.66 (-2.90%) ▼|AMGN433.06+3.18 (+0.74%) ▲|AMT175.51-0.19 (-0.11%) ▼|AMZN254.66-5.12 (-1.97%) ▼|AVGO367.78-2.56 (-0.69%) ▼|AXP326.86-3.32 (-1.00%) ▼|BA206.77-1.01 (-0.49%) ▼|BAC62.37+0.43 (+0.69%) ▲|BKNG199.46+0.37 (+0.18%) ▲|BLK1,136.45-19.16 (-1.66%) ▼|BMY67.03+0.22 (+0.32%) ▲|BNY160.60-0.68 (-0.42%) ▼|BRK-B504.70+0.67 (+0.13%) ▲|C133.09+1.47 (+1.11%) ▲|CAT781.69-15.78 (-1.98%) ▼|CL90.56+0.74 (+0.83%) ▲|CMCSA26.55-0.07 (-0.26%) ▼|COF213.56-0.96 (-0.45%) ▼|COP135.00+2.51 (+1.89%) ▲|COST945.38+1.49 (+0.16%) ▲|CRM257.80+0.26 (+0.10%) ▲|CSCO109.17-1.33 (-1.20%) ▼|CVS97.09+3.18 (+3.39%) ▲|CVX208.95+2.81 (+1.36%) ▲|DE672.81+17.90 (+2.73%) ▲|DHR209.33-4.24 (-1.98%) ▼|DIS107.52-0.03 (-0.03%) ▼|DUK120.65+0.74 (+0.61%) ▲|EMR149.65-2.79 (-1.83%) ▼|FDX324.60-2.80 (-0.86%) ▼|GD369.27-2.09 (-0.56%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV884.54-13.99 (-1.56%) ▼|GILD148.38+2.04 (+1.39%) ▲|GM86.22-0.10 (-0.12%) ▼|GOOG332.96-2.45 (-0.73%) ▼|GOOGL336.07-3.29 (-0.97%) ▼|GS1,021.55+0.65 (+0.06%) ▲|HD321.78-6.06 (-1.85%) ▼|HON210.33-3.20 (-1.50%) ▼|IBM231.12-2.75 (-1.18%) ▼|INTC88.80-0.71 (-0.79%) ▼|INTU349.87-9.43 (-2.62%) ▼|ISRG368.92-7.94 (-2.11%) ▼|JNJ268.15+2.30 (+0.86%) ▲|JPM358.40+2.38 (+0.67%) ▲|KO88.53-0.14 (-0.16%) ▼|LIN483.89-5.69 (-1.16%) ▼|LLY1,171.93+15.20 (+1.31%) ▲|LMT551.37-6.41 (-1.15%) ▼|LOW201.78-2.92 (-1.43%) ▼|LRCX291.64-9.85 (-3.27%) ▼|MA587.12-2.19 (-0.37%) ▼|MCD261.14-0.54 (-0.21%) ▼|MDLZ62.38+0.31 (+0.50%) ▲|MDT91.80+1.15 (+1.27%) ▲|META578.60+6.26 (+1.09%) ▲|MMM170.74-1.09 (-0.63%) ▼|MO70.38+1.90 (+2.77%) ▲|MRK149.39+1.63 (+1.10%) ▲|MS214.04+0.72 (+0.34%) ▲|MSFT501.12-6.18 (-1.22%) ▼|MU954.46-4.28 (-0.45%) ▼|NEE82.79+0.45 (+0.55%) ▲|NFLX80.88-0.18 (-0.22%) ▼|NKE38.36-0.30 (-0.76%) ▼|NOW143.09-4.91 (-3.31%) ▼|NVDA218.48-2.02 (-0.92%) ▼|ORCL142.52-6.60 (-4.43%) ▼|PEP140.01-0.33 (-0.24%) ▼|PFE28.64+0.18 (+0.61%) ▲|PG147.83+2.71 (+1.87%) ▲|PLTR183.27-3.11 (-1.67%) ▼|PM190.77+3.47 (+1.85%) ▲|QCOM165.61-4.87 (-2.86%) ▼|RTX206.16-1.58 (-0.76%) ▼|SBUX105.83-0.42 (-0.40%) ▼|SCHW108.78-1.04 (-0.95%) ▼|SO88.11+0.11 (+0.13%) ▲|SPG213.04+0.72 (+0.34%) ▲|T26.07+0.18 (+0.70%) ▲|TMO604.86-12.24 (-1.98%) ▼|TMUS181.95+1.51 (+0.84%) ▲|TSLA359.27-8.68 (-2.36%) ▼|TXN253.38-7.53 (-2.89%) ▼|UBER75.44-0.21 (-0.28%) ▼|UNH395.95+6.54 (+1.68%) ▲|UNP293.91-6.76 (-2.25%) ▼|UPS102.78-1.46 (-1.40%) ▼|USB61.23-0.36 (-0.58%) ▼|V376.86-2.52 (-0.66%) ▼|VZ50.30+0.28 (+0.55%) ▲|WFC86.87+0.48 (+0.55%) ▲|WMT106.07+1.20 (+1.14%) ▲|XOM163.12+2.17 (+1.35%) ▲|
24.1 C
New York
Tuesday, September 1, 2026

Tag: sites

newssourceFORcompanyinformationcontent1releasesmarket

Andersen Corporate Foundation Announces $1.2 Million in Spring 2026 Grants

BAYPORT, Minn., June 15, 2026 /PRNewswire/ -- The Andersen Corporate Foundation has committed over $1.2 million to 86 nonprofit organizations in its spring 2026...

Anta Scaffolding Strengthens One-Stop Scaffolding Solutions for Middle East and South American Markets

SUZHOU, China, June 15, 2026 /PRNewswire/ -- This month, Suzhou Anta Scaffolding Engineering Co., Ltd. (Anta Scaffolding), a Chinese scaffolding manufacturer and supplier, announced that...

Four Republic Services Employees Named Industry’s Best at 2026 National Waste & Recycling Association’s Awards Gala

National Waste & Recycling Association recognized two company drivers, an operator and a technician for outstanding safety, performance and servicePHOENIX, June 15, 2026 /PRNewswire/...

Ampace Unveils ‘Meet All, Green More’ Vision at Intersolar Europe 2026

Newly Launched UniC AG440 and PR-S3 Elite to Provide Full-Scenario Energy Storage Across C&l and Residential ApplicationsMUNICH, June 15, 2026 /PRNewswire/ -- Ampace, a...

SINEXCEL Partners with Tokyo Developer Namcha Barwa to Jointly Execute Japanese Utility-Scale BESS Projects

TOKYO, June 15, 2026 /PRNewswire/ -- SINEXCEL (300693.SZ) and Namcha Barwa Co., Ltd., a Tokyo-based clean-energy developer, signed a strategic cooperation agreement covering the...

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology...

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab’s potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026...

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSites

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers